Taxanes and Capecitabine in Combination: Rationale and Clinical Results

Heidelberger, 1957, Fluorinated pyrimidines: a new class of tumor-inhibitory compounds, Nature, 179, 663, 10.1038/179663a0 Diasio, 1989, Clinical pharmacology of 5-fluorouracil, Clin Pharmacokinet, 16, 215, 10.2165/00003088-198916040-00002 Mandel, 1969, The incorporation of 5-FU into RNA and its molecular consequences, Prog Mol Subcell Biol, 1, 82, 10.1007/978-3-642-46200-9_4 Santi, 1974, Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate, Biochemistry, 13, 471, 10.1021/bi00700a012 Lu, 1995, Dihydropyrimidine dehydrogenase activity in human liver: population characteristics and clinical implication in 5-FU chemotherapy, Clin Pharmacol Thera, 58, 512, 10.1016/0009-9236(95)90171-X Cameron, 1994, Continuous 5-fluorouracil in the treatment of breast cancer, Br J Cancer, 70, 120, 10.1038/bjc.1994.259 Ishikawa, 1998, Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts, Cancer Res, 58, 685 Jones, 1998, New developments in angiogenesis: a major mechanism for tumor growth and target for therapy, Cancer J Sci Am, 4, 209 Miwa, 1998, Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue, Eur J Cancer, 34, 1274, 10.1016/S0959-8049(98)00058-6 Budman, 1998, Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine, J Clin Oncol, 16, 1795, 10.1200/JCO.1998.16.5.1795 Bollag, 1980, Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine, Eur J Cancer, 16, 427, 10.1016/0014-2964(80)90221-2 Hartmann, 1980, [5'-deoxy-5-fluoruridine, a new antineoplastic pyrimidine antimetabolite], Schweiz Med Wochenschr, 110, 1078 Ishikawa, 1997, Xeloda™ (capecitabine): an orally available tumor-selective fluoropyrimidine carbamate, Proc Am Soc Clin Oncol, 16, 208a Schuller, 2000, Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients, Cancer Chemother Pharmacol, 45, 291, 10.1007/s002800050043 Mackean, 1998, Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer, J Clin Oncol, 16, 2977, 10.1200/JCO.1998.16.9.2977 Cassidy, 1998, A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors, Clin Cancer Res, 4, 2755 Van Cutsem, 2000, Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study, J Clin Oncol, 18, 1337, 10.1200/JCO.2000.18.6.1337 Blum, 1999, Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer, J Clin Oncol, 17, 485, 10.1200/JCO.1999.17.2.485 Blum, 1999, A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer, Proc Am Soc Clin Oncol, 18, 107a Moiseyenko, 1998, A randomized phase II study of Xeloda™ (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy, Ann Oncol, 9, 620a O'Shaughnessy, 1998, A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged > 55 years, Proc Am Soc Clin Oncol, 17, 103a O'Shaughnessy, 2000, A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine), Proc Am Soc Clin Oncol, 19, 104a Michaud, 2000, Improved therapeutic index with lower dose capecitabine in metastatic breast cancer (MBC) patients (pts), Proc Am Soc Clin Oncol, 19, 104a Eda, 1993, Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine, Cancer Chemother Pharmacol, 32, 333, 10.1007/BF00735915 Schiff, 1979, Promotion of microtubule assembly in vitro by taxol, Nature, 277, 665, 10.1038/277665a0 Bogdan, 1992, Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages, J Leukoc Biol, 52, 119, 10.1002/jlb.52.1.119 Sawada, 1998, Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts, Clin Cancer Res, 4, 1013 Sawada, 1999, X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts, Clin Cancer Res, 5, 2948 Villalona-Calero, 1999, Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J Clin Oncol, 17, 1915, 10.1200/JCO.1999.17.6.1915 Villalona-Calero, 2001, A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients, Ann Oncol, 12, 605, 10.1023/A:1011181010669 Perez-Manga, 2000, Efficacy and safety of capecitabine (Xeloda®) in combination with paclitaxel in patients with locally advanced or metastatic breast cancer: preliminary results of a phase II study, Breast Cancer Res Treat, 64, 124 Pronk, 2000, A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours, Br J Cancer, 83, 22, 10.1054/bjoc.2000.1160 O'Shaughnessy, 2000, Results of a large phase III trial of Xeloda/taxotere combination therapy versus taxotere monotherapy in patients with metastatic breast cancer, Breast Cancer Res Treat, 64 Vukelja, 2001, Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results, Breast Cancer Res Treat, 69, 269 Seidman, 1999, Single-agent paclitaxel in the treatment of breast cancer: phase I and II development, Semin Oncol, 26, 14 Perez, 1999, A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer, Proc Am Soc Clin Oncol, 18, 126a Hainsworth, 1998, Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer, J Clin Oncol, 16, 2164, 10.1200/JCO.1998.16.6.2164 Burstein, 2000, Docetaxel administered on a weekly basis for metastatic breast cancer, J Clin Oncol, 18, 1212, 10.1200/JCO.2000.18.6.1212 Elza-Brown, 2000, A phase I study of capecitabine and weekly paclitaxel in advanced solid tumors, Proc Am Soc Clin Oncol, 19, 237a Villalona-Calero, 2000, A phase I trial of capecitabine in combination with weekly docetaxel in patients with solid malignancies, Breast Cancer Res Treat, 64, 125